KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024)

Historic Acquisitions for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Q4 2024 value amounting to -$277.1 million.

  • Recursion Pharmaceuticals' Acquisitions fell 39038732.39% to -$277.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$277.0 million, marking a year-over-year decrease of 39028732.39%. This contributed to the annual value of -$277.1 million for FY2024, which is 1492733.19% down from last year.
  • Recursion Pharmaceuticals' Acquisitions amounted to -$277.1 million in Q4 2024, which was down 39038732.39% from $71000.0 recorded in Q4 2023.
  • Recursion Pharmaceuticals' 5-year Acquisitions high stood at $71000.0 for Q4 2023, and its period low was -$277.1 million during Q4 2024.